Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > ABRAXANE Meets Primary Endpoint in Phase III CA033 Study

FDAnews Drug Daily Bulletin

Oct. 3, 2012 | Vol. 9 No. 194

ABRAXANE Meets Primary Endpoint in Phase III CA033 Study

Celgene said its unit Celgene International Sàrl announced results of its Phase III, randomized, international study of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in chemotherapy-naïve patients with metastatic melanoma.
RTTNews

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Full Issue FDA Advisers Recommend Merck Insomnia Drug; Downplay Need for Additional Trials Senate Preps Track-and-Trace, Compounding Reform Bills for Floor Vote Ranbaxy Compliance Reforms Reflect FDA Manufacturing Recommendations

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.